Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim

Status and phase: Completed; Phase 4

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Tiotropium Bromide Inhalation Powder

Study type: Interventional

Funder types: Industry

Identifiers

NCT00106821

205.294

Details and patient eligibility

About

The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.

Enrollment: 166 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female of African descent
• 40 years of age or older
• Diagnosis of COPD
• History of smoking at least one pack per day for at least 10 years
• Currently experiencing shortness of breath at least with exertion

Exclusion criteria

• Asthma
• Recent myocardial infarction or hospitalization for congestive heart failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind